Cotarla I et al. Treatment decision drivers in stage III non-small-cell lung cancer: Outcomes of a web-based survey of oncologists in the United States. JCO Oncol Pract 2020;16(10):e1232-42. Abstract
Datta P et al. Durvalumab treatment initiation delays in patients with unresectable stage III non–small cell lung cancer treated at Veterans Health Administration facilities. ASCO2022;Abstract 8556.
Girard N et al. PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. ESMO 2021;Abstract 1171MO.
Herbst RS et al. COAST: An open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol 2022;[Online ahead of print]. Abstract
Sankar K et al. Real world outcomes versus clinical trial results of durvalumab maintenance in veterans with stage III non-small cell lung cancer. Cancers (Basel) 2022;14(3):614. Abstract
West HJ. Jarring discordance between idealized and real-world management in stage III non-small-cell lung cancer. JCO Oncol Pract 2020;16(10):628-30. Abstract
Jeffrey Bradley, MD
Banfill K et al. Cardiac toxicity of thoracic radiotherapy: Existing evidence and future directions. J Thorac Oncol 2021;16(2):217-27. Abstract
Martinez-Marti A et al. COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. ESMO 2021;Abstract LBA42.
Naidoo J et al. Immune-related pneumonitis after chemoradiotherapy and subsequent immune checkpoint blockade in unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 2020:21(5):e435-44. Abstract
Spigel DR et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022;40(12):1301-11. Abstract
David R Spigel, MD
Delasos L et al. Texture-based CT radiomics distinguishes radiation and immunotherapy induced pneumonitis in stage III NSCLC. ASCO 2022;Abstract 8555.
Durm GA et al. Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081. ASCO 2022;Abstract 8509.
Lebow ES et al. Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non–small cell lung cancer (NSCLC) treated with definitive radiation therapy. ASCO 2022;Abstract 8540.
Naidoo J et al. Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC. ASCO 2022;Abstract 8541.
Reck M et al. Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC. ASCO 2022;Abstract 8508.
Spigel DR et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. ASCO 2021;Abstract 8511.